PRESS RELEASE
News
-
-
-
PRESS RELEASE
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
New phase 2 data presented at ESMO Congress highlight AlphaMedix as a promising targeted alpha therapy for GEP-NETs, showing high response rates and potential to address unmet medical needs -
-
PRESS RELEASE
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Sanofi's high-dose influenza vaccine Efluelda/Fluzone High-Dose shows superior protection for older adults by reducing hospitalizations. FLUNITY-HD study details robust evidence published in The Lancet -
-
PRESS RELEASE
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
CHMP recommends Sanofi's Wayrilz for EU approval to treat immune thrombocytopenia, targeting disease root cause through multi-immune modulation. Positive phase 3 study results showcased rapid platelet response and symptom improvements -
-
PRESS RELEASE
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Sanofi announces negative CHMP opinion on Rezurock for chronic graft-vs-host disease in the EU but plans to seek re-examination. Rezurock has shown efficacy in clinical studies -
